Use of immunohistochemistry in melanocytic lesions

The great majority of cutaneous melanocytic lesions can be readily classified as one of the defined diagnostic entities, either benign or malignant. Therefore, only in a minority of lesions, it is necessary to employ ancillary techniques to help in the diagnosis. The most popular and probably the most helpful of these is immunohistochemistry: an area in which Dr McNutt has made some of his most important scholarly contributions. Following Dr McNutt’s lead, in this article, we describe the use of immunohistochemistry as a diagnostic aid in dermatopathology as well as the potential pitfalls commonly encountered in practice.

[1]  M. Wick,et al.  Immunostaining for MART‐1 in the interpretation of problematic intra‐epidermal pigmented lesions , 2007, Journal of cutaneous pathology.

[2]  B. Chwirot,et al.  Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours , 2007, Melanoma research.

[3]  J. Gershenwald,et al.  Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma , 2006, Clinical Cancer Research.

[4]  H. Skelton,et al.  Nuclear expression of the antiapoptotic protein survivin in malignant melanoma , 2006, Cancer.

[5]  Y. Hashimoto,et al.  Expression profiles of melanogenesis‐related genes and proteins in acquired melanocytic nevus , 2006, Journal of cutaneous pathology.

[6]  A. H. Diwan,et al.  Loss of claudin‐1 expression in tumor‐associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms , 2005, Journal of cutaneous pathology.

[7]  H. Kerl,et al.  Melan-A: Not a Helpful Marker in Distinction between Melanoma In Situ on Sun-Damaged Skin and Pigmented Actinic Keratosis , 2004, The American Journal of dermatopathology.

[8]  J. Brennick,et al.  False-positive Rate of the Immunoperoxidase Stains for MART1/MelanA in Lymph Nodes , 2004, The American journal of surgical pathology.

[9]  V. Prieto,et al.  Intraparenchymal Nevus Cell Aggregates in Lymph Nodes: A Possible Diagnostic Pitfall With Malignant Melanoma and Carcinoma , 2003, The American journal of surgical pathology.

[10]  N. S. Mcnutt,et al.  S100A6 Protein Expression is Different in Spitz Nevi and Melanomas , 2003, Modern Pathology.

[11]  L. Lowe,et al.  Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma , 2003, Journal of cutaneous pathology.

[12]  V. Prieto,et al.  Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation , 2002, Journal of cutaneous pathology.

[13]  R. Barr,et al.  S100-Positive Spindle Cells in Scars: A Diagnostic Pitfall in the Re-Excision of Desmoplastic Melanoma , 2002, The American Journal of dermatopathology.

[14]  V. Prieto,et al.  Atypical cells in human cutaneous re‐excision scars for melanoma express p75NGFR, C56/N‐CAM and GAP‐43: evidence of early Schwann cell differentiation , 2002, Journal of cutaneous pathology.

[15]  M. Mihm,et al.  Microphthalmia Transcription Factor Expression in Cutaneous Benign, Malignant Melanocytic, and Nonmelanocytic Tumors , 2001, The American journal of surgical pathology.

[16]  A. Folpe,et al.  Microphthalmia Transcription Factor and Melanoma Cell Adhesion Molecule Expression Distinguish Desmoplastic/Spindle Cell Melanoma From Morphologic Mimics , 2001, The American journal of surgical pathology.

[17]  C. Shea,et al.  Expression of the intermediate filament peripherin in extraskeletal myxoid chondrosarcoma , 2000, Journal of cutaneous pathology.

[18]  K. P. Fair,et al.  A comparison of melanin bleaching and azure blue counterstaining in the immunohistochemical diagnosis of malignant melanoma. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  C. Shea,et al.  Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma. , 1999, The American journal of surgical pathology.

[20]  N. S. Mcnutt,et al.  The S100 family of multipurpose calcium‐binding proteins , 1998, Journal of cutaneous pathology.

[21]  McNutt Ns.  "Triggered trap": nevoid malignant melanoma. , 1998 .

[22]  H. Kerl,et al.  Ancient melanocytic nevus. , 1998, Seminars in diagnostic pathology.

[23]  Yao-Tseng Chen,et al.  Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. , 1998, The American journal of surgical pathology.

[24]  F. Marincola,et al.  Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  W. Gerald,et al.  A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. , 1998, The American journal of surgical pathology.

[26]  N. McNutt.  "Triggered trap": nevoid malignant melanoma. , 1998, Seminars in diagnostic pathology.

[27]  R. Parwaresch,et al.  Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. , 1997, Journal of the American Academy of Dermatology.

[28]  N. S. Mcnutt,et al.  The intermediate filament peripherin is expressed in cutaneous melanocytic lesions , 1997, Journal of cutaneous pathology.

[29]  A. Cochran,et al.  Nodal nevi and cutaneous melanomas. , 1996, The American journal of surgical pathology.

[30]  A. Gown,et al.  HMB-45: A Review , 1996 .

[31]  M. Yaar,et al.  p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma , 1996, Journal of cutaneous pathology.

[32]  N. S. Mcnutt,et al.  Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity , 1995, Journal of cutaneous pathology.

[33]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[34]  B. Smoller,et al.  HMB‐45 recognizes stimulated melanocytes , 1989, Journal of cutaneous pathology.

[35]  A. Cochran,et al.  Immunohistpchemical demonstration of S‐100 protein and melanoma‐associated antigens in melanocytic nevi , 1988, Journal of cutaneous pathology.

[36]  A. Gown,et al.  Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. , 1986, The American journal of pathology.